Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-001088-29
    Sponsor's Protocol Code Number:CJDQ443B12201
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-08-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2022-001088-29
    A.3Full title of the trial
    KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
    KontRASt-06 : étude de phase II, en ouvert, évaluant l’activité et la tolérance de JDQ443 en monothérapie en première ligne de traitement chez les patients atteints de cancer bronchique non à petites cellules localement avancé ou métastatique avec mutation KRAS G12C et ayant une expression de PD-L1 < 1 % ou une expression de PD-L1 ≥ 1 % et des co-mutations STK11
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
    Etude de phase II, en ouvert, évaluant l’activité et la tolérance de JDQ443 en monothérapie en première ligne de traitement chez les patients atteints de cancer bronchique non à petites cellules localement avancé ou métastatique avec mutation KRAS G12C et ayant une expression de PD-L1 < 1 % ou une expression de PD-L1 ≥ 1 % et des co-mutations STK11
    A.4.1Sponsor's protocol code numberCJDQ443B12201
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Pharma AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Pharma S.A.S
    B.5.2Functional name of contact pointInformation&Communication Médicales
    B.5.3 Address:
    B.5.3.1Street Address8/10 rue Henry Sainte Claire Deville, CS 40150
    B.5.3.2Town/ cityRueil-Malmaison
    B.5.3.3Post code92563
    B.5.3.4CountryFrance
    B.5.4Telephone number+33155476600
    B.5.5Fax number+33155476100
    B.5.6E-mailicm.phfr@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameJDQ443
    D.3.2Product code JDQ443
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot established yet.
    D.3.9.2Current sponsor codeJDQ443
    D.3.9.3Other descriptive nameJDQ443
    D.3.9.4EV Substance CodeSUB218494
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation
    Cancer bronchique non à petites cellules localement avancé ou métastatique muté KRAS G12C et avec une expression de PD-L1 < 1 % ou une expression de PD-L1 ≥ 1 % et des co-mutations STK11.
    E.1.1.1Medical condition in easily understood language
    locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer
    Cancer bronchique non à petites cellules localement avancé ou métastatique muté KRAS G12C
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the antitumor activity of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS G12C mutation and a PD-L1 expression < 1%, regardless of STK11 mutation status (cohort A).
    Evaluer l’activité antitumorale de JDQ443 en monothérapie, comme traitement de première ligne de patients atteints de CBNPC localement avancé ou métastatique dont les tumeurs présentent la mutation KRAS G12C et une expression de PD-L1 < 1 %, indépendamment du statut mutationnel de STK11 (Cohorte A).
    E.2.2Secondary objectives of the trial
    • To assess the antitumor activity of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥1% and an STK11 co-mutation (cohort B).
    • To assess duration of response (DOR) in both cohorts.
    Evaluer l’activité antitumorale de JDQ443 en monothérapie, comme traitement de première ligne de patients atteints de CBNPC localement avancé ou métastatique dont les tumeurs présentent la mutation KRAS G12C, une expression de PD-L1 ≥ 1% et co-mutations STK11 (Cohorte B).
    Evaluer la durée de la réponse (DDR) dans les 2 cohortes.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Histologically confirmed locally advanced (stage IIIb/IIIc not eligible for definitive chemoradiation or surgical resection with curative intent) or metastatic (stage IV) NSCLC without previous systemic treatment for metastatic disease. Prior (neo)adjuvant treatment with chemotherapy and/or immunotherapy, or prior radiotherapy administered sequentially or concomitantly with chemotherapy and/or immunotherapy for localized or locally advanced disease are accepted if the time between therapy completion and enrollment is > 12 months.
    • Presence of a KRAS G12C mutation (all participants) and:
    • Cohort A: PD-L1 expression < 1%, regardless of STK11 mutation status
    • Cohort B: PD-L1 expression ≥ 1% and an STK11 co-mutation
    • At least one measurable lesion per RECIST 1.1.
    • ECOG performance status ≤ 1.
    • Participants capable of swallowing study medication.
    Patients atteints de CBNPC histologiquement confirmé, à un stade localement avancé (stade IIIB/IIIC inéligible à une chimio radiothérapie définitive ou à une résection chirurgicale à but curatif) ou métastatique (stade IV), n’ayant pas reçu de traitement systémique antérieur pour le stade métastatique. Les patients qui ont reçu une chimiothérapie et/ou une immunothérapie antérieures en situation (néo)adjuvante, ou une radiothérapie antérieure de manière concomitante/séquentielle avec une chimiothérapie et/ou une immunothérapie pour un stade localisé ou localement avancé, sont éligibles si le temps écoulé entre le traitement antérieur et l’inclusion est > 12 mois.
    • Présence de la mutation KRAS G12C chez tous les patients et :
    o Cohorte A : expression de PD-L1 < 1 %, indépendamment du statut mutationnel de STK11 ;
    o Cohorte B : expression de PD-L1 ≥ 1%, et co-mutations STK11.
    • Présence d’au moins une lésion mesurable selon critères RECIST v1.1.
    • Indices de performance ECOG (pour Eastern Cooperative Oncology Group) ≤ 1.
    • Patients en mesure d’avaler le traitement à l’étude.
    E.4Principal exclusion criteria
    • Participants whose tumors harbor an EGFR-sensitizing mutation and/or ALK rearrangement by local laboratory testing. Participants with other known druggable alterations will be excluded, if required by local guidelines
    • Previous use of a KRAS G12C inhibitor or previous systemic treatment for metastatic NSCLC.
    • A medical condition that results in increased photosensitivity (i.e. solar urticaria, lupus erythematosus, etc).
    • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
    • Participants who are taking a prohibited medication (strong CYP3A inducers) that cannot be discontinued at least seven days prior to the first dose of study treatment and for the duration of the study
    Patients dont les tumeurs présentent une mutation activatrice EGFR (pour epidermal growth factor receptor) et/ou un réarrangement d’ALK (pour anaplastic lymphoma kinase) d’après les analyses du laboratoire local. Les patients qui présentent d’autres altérations connues pouvant être ciblées par un médicament seront inéligibles, si requis par les réglementations locales.
    • Traitement antérieur par un inhibiteur de KRAS G12C ou traitement systémique antérieur pour un CBNPC métastatique.
    Toute pathologie qui engendre une photosensibilité exacerbée (c’est-à-dire urticaire solaire, lupus érythémateux, etc.).
    • Présence de métastases actives du système nerveux central et/ou méningite carcinomateuse.
    • Patients qui reçoivent un traitement interdit (activateurs puissants du CYP3A) qui ne peut pas être arrêté au moins 7 jours avant la première dose de traitement à l’étude et pendant toute la durée de l’étude.
    E.5 End points
    E.5.1Primary end point(s)
    Overall response rate (ORR), defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent review committee (BIRC).
    Taux de réponse global (TRG), défini par la proportion de patients qui ont une réponse complète (RC) ou une réponse partielle (RP) comme meilleure réponse globale (MRG), selon les critères RECIST v1.1 (pour Response Evaluation Criteria in Solid Tumors version 1.1) par le comité indépendant de revue en aveugle (BIRC pour Blinded Independent Review Committee).
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint of the study is ORR, defined as the proportion of participants with a confirmed CR/PR as BOR. BOR is defined as the best response recorded from the start of the treatment until disease progression per RECIST 1.1 by BIRC. CR and PR must be confirmed by repeat assessments that should be performed not less than 4 weeks after the criteria for response were first met. Responses documented after the use of any new anti-neoplastic therapy will be considered as non-response.
    E.5.2Secondary end point(s)
    • ORR per RECIST 1.1 by BIRC.
    • DOR, defined as the time from the first occurrence of a PR or a CR per RECIST 1.1 by BIRC to the occurrence of disease progression or death due to any cause.
    • PFS, defined as the time from the date of enrollment to the date of the first documented disease progression per RECIST 1.1 by BIRC or date of death due to any cause.
    • OS, defined as the time from the date of enrollment to the date of death due to any cause.
    • Disease control rate (DCR), defined as the proportion of participants with a BOR of confirmed CR, PR and stable disease (SD) per RECIST 1.1 by BIRC.
    Time to response (TTR), defined as the time from the date of enrollment to the first documented response of either CR or PR per RECIST 1.1 by BIRC.
    • ORR, DOR, DCR, TTR and PFS per RECIST 1.1 by local radiology assessment.
    • ORR, DOR, DCR and TTR per RECIST 1.1 by BIRC and by local radiology assessment.
    • PFS and OS
    • Type, frequency and severity of adverse events, changes in laboratory values, vital signs, electrocardiograms (ECGs).
    • Concentration of JDQ443 in plasma and derived PK parameters, as appropriate.
    • Time to definitive deterioration (TTD) in the NSCLC-SAQ total score, and TTD in the physical functioning (PF) scale of the EORTC QLQ-C30
    • Change from baseline to each treatment visit and EOT for NSCLC-SAQ total score, pain, cough, dyspnea and items.
    • Change from baseline to each treatment visit and EOT for all EORTC-QLQ C30 domains, subscales and items
    • Change from baseline to each treatment visit and to EOT for the FACT GP5
    Taux de réponse global selon les critères RECIST v1.1 par le BIRC.
    DDR, définie comme le temps écoulé entre la première survenue d’une RP ou d’une RC, selon les critères RECIST v1.1 par le BIRC, et une progression de la maladie ou le décès du patient, quelle qu’en soit la cause.
    SSP définie comme le temps écoulé entre la date d’inclusion dans l’étude et la date de la première progression de la maladie documentée selon les critères RECIST v1.1 par le BIRC, ou du décès du patient, quelle qu’en soit la cause.
    SG, définie comme le temps écoulé entre la date d’inclusion dans l’étude et la date du décès du patient, quelle qu’en soit la cause.
    Taux de contrôle de la maladie (TCM), défini comme la proportion de patients qui ont comme MRG une RC, une RP ou une maladie stable (MS) confirmée, selon les critères RECIST v1.1 par le BIRC.
    Temps jusqu’à la réponse (TR), définie comme le temps écoulé entre la date d’inclusion dans l’étude et la date de la première RC ou RP documentée, selon les critères RECIST v1.1 par le BIRC.
    TRG, DDR, TCM, TR et SSP selon les critères RECIST v1.1 lors de l’évaluation radiologique réalisée localement.
    TRG, DDR, TCM et TR selon les critères RECIST v1.1 par le BIRC et l’évaluation radiologique réalisée localement.
    SSP et SG.
    Type, fréquence et sévérité des effets indésirables, modifications des paramètres biologiques, signes vitaux et électrocardiogrammes.
    Concentration de JDQ443 dans le plasma et paramètres PK dérivés, le cas échéant.
    Temps jusqu’à la détérioration définitive (TDD), d’après le score total NSCLC-SAQ (pour Non–Small Cell Lung Cancer Symptom Assessment Questionnaire), et d’après l’échelle fonctionnelle physique du EORTC QLQ-C30 (pour European Organisation for Research and Treatment of Cancer core Quality of Life Questionnaire)
    Modification, depuis la baseline et entre chaque visite durant la période de traitement, et la fin du traitement du score total NSCLC-SAQ pour la douleur, la toux, la dyspnée et les items associés.
    Changements dans les réponses pour tous les domaines, sous-échelles et items du EORTC QLQ-C30 entre la baseline et chaque visite de la période de traitement, et la fin du traitement.
    Changements dans les réponses pour le questionnaire FACT GP5 (pour Functional Assessment of Cancer Therapy - Item GP5) entre la baseline et chaque visite de la période de traitement, et la fin du traitement.
    E.5.2.1Timepoint(s) of evaluation of this end point
    For the key secondary endpoint, ORR per RECIST 1.1 by BIRC in cohort B, the same definition as in the Protocol, Section 9.3.1 applies. Treatment with JDQ443 will be considered to have clinically relevant efficacy in cohort B if an ORR of ≥ 40% is observed with the lower bound of the 95% confidence interval ≥ 20%.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA42
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Brazil
    China
    India
    Malaysia
    Singapore
    Thailand
    United States
    Austria
    France
    Bulgaria
    Netherlands
    Spain
    Germany
    Greece
    Italy
    Belgium
    Hungary
    Portugal
    Turkey
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 120
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state7
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 63
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are currently no specific plans.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-11-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-09-22
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 20:25:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA